Reviewer1: MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma through inactivation of AKT signalling pathway This manuscript investigates the inhibitory role of the cannabinoid receptor 2 (CB2) agonist MDA19 in cancer progression, by focusing on hepatocellular carcinoma (HCC) cell lines (Hep3B and HepG2). This evidence concerns the gene AKT1 and hepatocellular carcinoma.